Author

Rolf Wagenaar

Observed name: Rolf J Wagenaar

Institution: Basilea Pharmaceutica (Switzerland)

Observed institution: Basilea Pharmaceutica (Switzerland)

ORCID: 0009-0006-7325-4257

Observed ORCID: 0009-0006-7325-4257

OpenAlex ID: A5084500752

Unfavorable Outcomes and Their Risk Factors in Hospitalized Patients with Staphylococcus aureus Bacteremia in the US: A Multicenter Retrospective Cohort Study, 2020–2022

2025 · Marya D. Zilberberg, Brian H. Nathanson, et al. · Antibiotics · 4

570. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Continuous Infusion Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)

2026 · Sujata M Bhavnani, Jeffrey P Hammel, et al. · Open Forum Infectious Diseases

CO111 Costs and Complications of Hospitalization among Survivors of S. aureusbacteremia in the US: A Multicenter Retrospective Cohort Study, 2020-2022

2025 · Marya Zilberberg, Brian H. Nathanson, et al. · Value in Health

Works count: 3

Citation count: 4

H-index: 1

I10-index: